toxylact: a07aa02 smecta

The first professional lActological database in the word

Diosmectite (ATC class A07AA02) is an intestinal adsorbent used for symptomatic treatment of acute and chronic diarrhoea and functional bowel disorders; current regulatory advice is to avoid its use during breastfeeding because of concerns about trace lead impurities and lack of lactation data.hsa+4

Pharmacological class and mechanism

Diosmectite belongs to ATC class A07AA02, “intestinal adsorbents,” and is a natural aluminium–magnesium silicate clay with high surface area and adsorption capacity. It binds bacterial toxins, viruses, bile salts and excess water in the intestinal lumen, and reinforces the mucus barrier by adhering to mucopolysaccharides, thereby reducing stool liquidity and mucosal irritation.atcddd.fhi+3

Therapeutic indications and dosing

Oral diosmectite is indicated for treatment of acute watery diarrhoea in children aged ≥2 years and adults, usually as an adjunct to oral rehydration therapy, and for chronic functional diarrhoea and pain related to functional bowel disorders in adults. Typical adult dosing is 3 sachets per day for acute diarrhoea and up to 9 g/day for other gastrointestinal symptoms, while paediatric regimens use 4 sachets/day for the first 3 days followed by 2 sachets/day for 4 days, in children ≥2 years.pmc.ncbi.nlm.nih+3

Safety profile and general toxicology

Diosmectite is minimally absorbed from the gastrointestinal tract, so systemic exposure to the clay itself is expected to be negligible. The main dose‑related adverse reaction is constipation, and rare events include bezoar formation with overdose and potential interference with absorption of concomitant orally administered medicines if taken too close together.pmc.ncbi.nlm.nih+4

Concerns raised by several authorities relate to naturally occurring trace elements such as lead in clay-based products, leading to restrictions on use in young children and in pregnant or breastfeeding women as a precautionary measure. In practice, diosmectite should be avoided in patients with chronic constipation, bowel obstruction or severe abdominal pain of unknown origin, and rehydration remains the primary treatment of diarrhoea.npra+6

Lactation toxicology and clinical recommendations

No clinical pharmacokinetic or controlled safety studies of diosmectite in breastfeeding women or breastfed infants have been published, and human milk transfer data are lacking. Given its negligible gastrointestinal absorption, significant passage of the clay itself into breast milk is unlikely, but the presence of trace lead as an impurity has prompted multiple regulators and manufacturers to explicitly advise against use of Smecta (diosmectite) during breastfeeding as a precaution.drugoffice+5

In the absence of robust lactation safety data and considering the availability of alternative antidiarrhoeal options with better-characterised breastfeeding compatibility (for example, loperamide and kaolin‑pectin, which are recommended by some authorities for nursing mothers), dio smectite-containing products should generally be avoided in lactating women. If a breastfeeding mother has been inadvertently exposed, clinically relevant systemic or infant toxicity from diosmectite itself is unlikely, but theoretical lead exposure warrants monitoring of the infant for gastrointestinal or neurologic symptoms and consideration of switching to alternative therapies.breastfeedingnetwork+6

Practical use in breastfeeding women

For acute diarrhoea in breastfeeding women, oral rehydration, dietary adjustment and antidiarrhoeals with established lactation safety profiles are preferred over diosmectite. Where diosmectite is considered despite current restrictions, its use should be limited to short courses at the lowest effective dose, only after individual risk–benefit assessment and informed consent, and ideally in settings where infant follow‑up

Recent ARTICLES

July 24

Abdominal Compartment Syndrome

PWhile the formal term and its consensus definitions were codified by the World Society of the Abdominal Compartment Syndrome (WSACS) only in the early 2000s, the physiological underpinnings have been observed for over 150 years. In 1863, the French physiologist Etienne-Jules Marey was the first to document the reciprocal relationship between intra-abdominal pressure (IAP) and respiratory function, noting that the expansion of the abdominal cavity directly impacted the efficiency of the thoracic bellows.

July 18

Assessment of Postoperative Fever

For the physician and the student of medicine, the assessment of postoperative fever is not merely a task of temperature monitoring, but a diagnostic journey that requires a nuanced understanding of immunology, physiology, and clinical timing. Guided by the principle of "Primum non nocere," this report seeks to bridge the gap between complex pathophysiological mechanisms and the empathetic care of the patient, providing a comprehensive framework for identifying, understanding, and managing this common clinical challenge.

July 14

Clinical Review of Congenital and Acquired Cystic Kidney Diseases

The healing arts, as envisioned by the ancient traditions of medicine, seek not merely the eradication of pathology but the restoration of a delicate equilibrium between the body’s internal environment and the external world. In the realm of nephrology, cystic diseases of the kidney represent a profound disruption of this balance.

Spotlight

A Comprehensive Analysis of Complement System Deficiencies in Pediatric and Adult Populations

The human immune system is a tapestry of ancient evolutionary mechanisms and highly specialized adaptive responses, woven together to maintain the delicate equilibrium of health. At the heart of this architecture lies the complement system, a complex network of over fifty proteins that function as the primordial vanguard of innate immunity. Named for its ability to "complement" the action of antibodies, this system serves as a bridge between the immediate, non-specific recognition of pathogens and the targeted, long-term memory of the adaptive immune response. However, when this sentinel falls silent due to genetic or acquired deficiencies, the result is a state of nuanced immunosuppression that significantly alters the human clinical landscape across all ages.